INDUSTRY SESSIONS

INDUSTRY SESSIONS

WEDNESDAY, 20 FEBRUARY 2019

MINIMEDTM 670G SYSTEM: PRACTICAL GUIDANCE TO ONBOARD YOUR PATIENTS SUCCESSFULLY

14:30-16:00, Hall A2

WORKSHOP IS ORGANISED AND SUPPORTED BY: Medtronic

Prof. Ohad Cohen, Israel

Dr. Anna-Kaisa Tuornaala, Finland

Mr.David Turner, UK

Target audience:

  • HCPs naïve to the MiniMedTM 670G system & planning to start using it in the coming weeks.
  • Up to 60 attendees on a  first come first serve basis.


TRANSLATING CLINICAL EVIDENCE FOR SENSOR-BASED GLUCOSE MONITORING AND TECHNOLOGICAL INNOVATIONS TO THE FRONT LINES OF CLINICAL PRACTICE

14:30-16:00, Hall A3

SYMPOSIUM IS ORGANISED AND SUPPORTED BYAbbott

CHAIR: Prof. Jochen Seufert, MD, Germany

14:30-14:40       INTRODUCTION AND WELCOME

THE EVOLVING LANDSCAPE OF SENSOR-BASED TECHNOLOGY FOR OPTIMIZING CLINICAL OUTCOMES ACROSS THE COMPREHENSIVE SPECTRUM OF TYPE 1 AND TYPE 2 DIABETES CARE
Prof. Jochen Seufert, MD, Germany

14:40-15:00       TRANSLATING LANDMARK TRIALS AND META-ANALYSES TRIALS TO THE FRONT LINES OF DIABETES CARE
Gerry Rayman, MDUK

15:00-15:20      UPTAKE AND UPSHOT: SENSOR TECHNOLOGY-BASED BEHAVIORS, RESULTS, AND OUTCOMES IN THE REAL WORLD: HOW DO PERSONS WITH DIABETES USE, INTERACT WITH AND OPTIMIZE SAFETY AND HBA1C GOAL ATTAINMENT USING SENSOR-BASED GLUCOSE MONITORING?
Ramzi Ajjan, MD, PhD, UK

15:20-15:50      REAL WORLD, INTERACTIVE CASE MANAGEMENT SESSIONS WITH THE FACULTY: CLINICAL DECISION-MAKING USING SENSOR-BASED GLUCOSE MONITORING TECHNOLOGY
Jochen Seufert, Germany
Program Chair and Faculty Moderate Case Management Sessions Focused on Technology-Mediated Management of Challenging Persons with Diabetes 

15:50-16:00      PROGRAM CHAIR'S SUMMARY AND VISION STATEMENT THE FOUNDATIONAL ROLE OF SENSOR-BASED GLUCOSE MONITORING TECHNOLOGY—HOW SHOULD CLINICIANS AND PATIENTS COLLABORATE TO IMPROVE CLINICAL OUTCOMES AND PATIENT CARE?
Prof. Jochen Seufert, MD, Germany


CONNECTED SELF-MONITORING OF BLOOD GLUCOSE – "A FUTURE PERSPECTIVE"

14:30–16.00, Hall M1 

SYMPOSIUM IS ORGANISED AND SUPPORTED BY: LifeScan

CHAIR:  Steven Edelman – Chair US

14.30–14.35     WELCOME & INTRODUCTION
Steven Edelman – Chair US

14.35–14.50     THE CONSENSUS VALUE – CONNECTED SELF-MONITORING OF BLOOD GLUCOSE

 Steven Edelman, US

14.50–15.05     VALUE OF TECHNOLOGIES IN MONITORING (BLOOD) GLUCOSE

 Oliver Schnell, Germany

15.05–15.25     RIGHT METER, RIGHT PATIENT – OPTIMIZING THE BENEFIT

 Katharine Barnard, UK

15.25–15.40     LATEST CLINICAL EVIDENCE

 Mike Grady, UK

15.40–16.00     REVEALING THE FUTURE

 David DeJonghe, US

16.00–16.30     QUESTIONS & ANSWERS

 

SGLT-2 INHIBITORS IN TYPE 1 DIABETES – QUO VADIS?

16:15 – 17:45, Plenary Hall 7

SYMPOSIUM ORGANIZED AND SUPPORTED BY: Sciarc

CHAIR:  Phillip Moshe, Israel

16:15–16:20      WELCOME & INTRODUCTION
 Phillip Moshe, Israel

16:20–16:35      UNMET MEDICAL NEEDS

 Russell-Jones David, UK

16:35–16:50      SGLT-2 INHIBITORS IN TYPE 1 DIABETES

 Mathieu Chantal, Belgium

16:35–16:50      SGLT-2 INHIBITORS AND TECHNOLOGY

 Danne Thomas, Germany

17:05–17:20      ARE SGLT-2 INHIBITORS NEPHROPROTECTIVE?

 Groop Per-Henrik, Finland

17:20–17:35      SGLT-2 INHIBITORS IN TYPE 1 DIABETES – CARDIOPROTECTIVE?

 Battelino Tadej, Slovenia 

17:35–17:45       DISCUSSION

 Phillip Moshe, Israel


*Supported by a Medical Education Grant from AstraZeneca 


GUARDIANTM CONNECT CGM: WHY PREDICTION IS KEY FOR SUSTAINED BETTER OUTCOMES

16:15-17:45, Hall A2

WORKSHOP IS ORGANISED AND SUPPORTED BY: Medtronic

Prof. Ohad Cohen, Israel

Laurent Barsin, Switzerland


ThurSDAY, 21 FEBRUARY 2019

AUTOMATING INSULIN DELIVERY TO MAXIMISE GLYCAEMIC CONTROL WITH SMARTGUARDTM TECHNOLOGY


10:30 – 12:00, PLENARY Hall A7


SYMPOSIUM IS ORGANISED AND SUPPORTED BY: Medtronic

CHAIR:  Dr. Scott Lee, United States

 

10:30-10:40     OPENING

                    Dr. Scott Lee, United States

 

10:40-11:00     PREVENTING HYPOGLYCEMIA WITH PREDICTIVE INSULIN SUSPENSION: 

                   INSIGHTS FROM THES SMILE STUDY

                   Dr. Pratik Choudhary, United Kingdom

 

11:00-11:30     MINIMEDTM 670G SYSTEM: INCREASING TIME IN RANGE WITH HYBRID CLOSED LOOP THERAPY

                   Dr. Jennifer Sherr, United States

 

11:30-11:45     LOOKING TOWARD THE FUTURE:  NEXT STEPS IN THE ADVANCEMENT OF CLOSING THE LOOP

                   Ali Dianaty, United States


11:45–12:00   QUESTIONS & ANSWERS


 

DEXCOM’S LEADING TECHNOLOGY DRIVING THE NEXT PHASE OF DIABETES INNOVATION – CLOSED-LOOP THERAPY AND CGM BASED-DECISION SUPPORT 

13:00-14:30 Hall A3


SYMPOSIUM IS ORGANISED AND SUPPORTED BY: Dexcom

CHAIR:  Prof. Dr. Lutz Heinemann, PhD, Germany

13:00-13:15       OPENING
Prof. Dr. Lutz Heinemann, PhD, Germany

13:15-13:45       PROGRESS TOWARD CLOSED-LOOP THERAPY USING DEXCOM CGM – RESEARCH AND CLINICAL TRIAL UPDATES

Dr. Boris Kovatchev, PhD, USA

13:45-14:05      CGM-BASED DECISION SUPPORT FOR MULTIPLE DAILY INJECTION PATIENTS USING DEXCOM CGM

Dr. Marc D. Breton, PhD, USA

 

14:05-14:25      THE UP AND COMING NEXT TECHNOLOGY INNOVATION FROM DEXCOM 

                    Jake Leach, USA

 

14:25-14:30     QUESTONS AND ANSWERS MEETING CLOSE

 


MINIMED 670G™ SYSTEM: ACHIEVING THE BEST OUTCOMES FOR YOUR PATIENTS

13:00-14:30, Hall A2

WORKSHOP IS ORGANISED AND SUPPORTED BY: Medtronic

Prof. Ohad Cohen, Israel

Dr. Anna-Kaisa Tuornaala, Finland

Target audience:

  • HCPs already experienced with the MiniMedTM 670G system.
  • Up to 60 attendees on a first come first serve basis.


VIEWING THE DIABETES SPECTRUM THROUGH A NEW LENS

15:00-16:30 PLENARY Hall A8

SYMPOSIUM IS ORGANISED AND SUPPORTED BY: Sanofi

CHAIR: Jay Skyler, USA

 

15:00–15:05     WELCOME AND INTRODUCTION

Jay Skyler, USA

 

15:05–15:20      CAUSE FOR CONCERN: WHAT DRIVES UNMET NEEDS IN DIABETES CARE

Lucia Novak, USA

15:20–15:40      ADJUSTING PERSPECTIVES: THE IMPORTANCE OF THE TITRATION PERIOD FOR BASAL INSULIN INITIATION

Robert Ritzel, Germany

 

15:40–16:00     UNIFYING PERSPECTIVES: IMPROVING OUTCOMES FOR PATIENTS WITH T1DM

Pratik Choudhary, UK

 

16:00–16:20      TIME IN RANGE AND GLUCOSE VARIABILITY: THE NEW GLYCEMIC METRICS TO CONSIDER!

Richard Bergenstal, USA

 

16:20–16:30      Q&A AND CLOSING REMARKS

Jay Skyler and panel of faculty

 

FRIDAY, 22 FEBRUARY 2019

SEVERE HYPOGLYCAEMIA: CLINICAL PRACTICE AND REAL-WORLD CHALLENGES

09:00-10:00, Hall M4

SYMPOSIUM IS ORGANISED AND SUPPORTED BY: Lilly

CHAIR: Tadej Battelino, Slovenia

09:00–09:05     WELCOME AND INTRODUCTION

                      Tadej Battelino, Slovenia

09:05-09:15      THE CLINICAL PROBLEM OF SEVERE HYPOGLYCAEMIA

                      Tadej Battelino, Slovenia

09:15-09:30      CHALLENGES OF LIVING WITH SEVERE HYPOGLYCAEMIA: THE NEED TO BE PREPARED

                       CajsaLindberg, Sweden - person with Type 1 Diabetes 

09:30-09:50        HYPOGLYCAEMIA: A CLINICIAN'S VIEW

                        Pratik Choudhary, United Kingdom

09:50–10:00        QUESTIONS AND ANSWERS, CLOSING REMARKS

                        All Faculty


INTEGRATED PERSONALISED DIABETES MANAGEMENT:  CONNECTING THE DOTS FOR TRUE RELIEF

10:30-12:00 PLENARY Hall A7
SYMPOSIUM IS ORGANISED AND SUPPORTED BY: Roche Diabetes Care

CHAIRS: Antonio Ceriello, Italy  and Rolf Hinzmann, Roche Diabetes Care, Germany

10:30–10:35     INTRODUCTION 

10:35–11:00     BIG DATA – REALLY THE FUTURE OF DIABETES MANAGEMENT?
Laura Furmanski, USA

11:00–11:25      DRUGS, DATA & TECHNOLOGY: HOW TO OVERCOME CLINICAL INERTIA

                    Oliver Schnell, Germany 

11:25–11:40      INSERTABLE CGM TECHNOLOGY WITH A 6 MONTH SENSOR WEAR  TIME:  LATEST CLINICAL INSIGHTS
Concetta Irace, Italy

11:40–11:55      TAKING CSII TO THE NEXT LEVEL: NEW MICRO PUMP SOLUTIONS AND FUTURE DEVELOPMENTS

Nick Oliver, UK 

11:55–12:00     CLOSING REMARKS

 

PURSUIT TOWARDS IDEAL MEALTIME INSULINS

15:00-16:30, PLENARY Hall A7

SYMPOSIUM IS ORGANISED AND SUPPORTED BY: Novo Nordisk

CHAIR: David Russell-Jones, UK

15:00–15:10     WELCOME & INTRODUCTION

                   David Russell-Jones, UK

15:10–15:30     CHANGING PARADIGM IN MEALTIME INSULINS

                   Christophe De Block, Belgium

15:30-15:50      FAST ACTING INSULIN ASPART – LATEST CLINICAL DATA

         Thomas Danne, Germany

15:50-16:10      TECHNOLOGICAL ADVANCEMENTS IN DIABETES CARE

         Hans De Vries, Germany

16:10-16:25     PANEL DISCUSSION

          Christophe De Block, Belgium, Thomas Danne, Germany, Hans De Vries, Germany

16:25-16:30     MEETING CLOSE

       David Russell-Jones, UK

 

DEXCOM CGM DATA DRIVING A ROBUST ECOSYSTEM TO SUPPORT IMPROVED PATIENT AND HCP EXPERIENCES AND UTILIZATION

16:40-18:00, Hall A2

WORKSHOP IS ORGANISED AND SUPPORTED BY: Dexcom

CHAIR:   Keri Leone MS, RD, CDE, USA

16:40 - 16:50     OPENING

Keri Leone MS, RD, CDE, USA

16:50-17:20      EXPANSION OF DEXCOM’S ECOSYSTEM THROUGH DATA PARTNERSHIPS AND INNOVATION

Nate Heintzman, PhD, USA

17:20-17:40        INTRODUCTION OF EMR INTEGRATION AND CGM:  BENEFITS TO HCP WORKFLOW AND PATIENT EXPERIENCE

TBD 

17:40-17:55        REAL WORLD EVIDENCE DATA AND TRENDS WITH DEXCOM CGM

John Welsh MD, USA

17:55-18:00      QUESTONS AND ANSWERS MEETING CLOSE

 

SLIM X2 INSULIN PUMP WITH BASAL-IQ™ PLGS TECHNOLOGY – REDUCING HYPOGLYCEMIA WITHOUT FINGERSTICKS

16:40–18.00, Hall M1


SYMPOSIUM IS ORGANISED AND SUPPORTED BY: Tandem Diabetes Care   

CHAIR:  John Sheridan,USA


16:40-17:00       USER EXPERIENCE RESEARCH AND THE DESIGN OF THE T: 

                      SLIM X2 INSULIN PUMP WITH BASAL-IQ TECHNOLOGY

               Steph Habif, EdD, MS, USA

17:00-17:20       A NOVEL WAY TO EVALUATE PATIENT OUTCOMES WITH THE ADOPTION OF 

                      NEW INSULIN PUMP TECHNOLOGIES

                       Peter Adolfsson, MD, Sweden

17:20-17:40       CLINICAL RESULTS OF THE PROLOG TRIAL FOR THE BASAL-IQ TECHNOLOGY

                        Jordan Pinsker, MD, USA

17:40-18:00        THE CARE MODEL – A SYSTEMATIC APPROACH FOR THE EVALUATION OF  

                      AUTOMATED INSULIN DELIVERY SYSTEMS

                      Gregory Forlenza, MD, USA

17.55-18.00        MEETING CLOSE

 






Keep Me Updated